Oxaliplatin

Catalog No.S1224 Synonyms: L-OHP

Oxaliplatin Chemical Structure

Molecular Weight(MW): 397.29

Oxaliplatin inhibits DNA synthesis by conforming DNA adducts in RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2, and HT-144 cells.

Size Price Stock Quantity  
USD 70 In stock
USD 120 In stock
USD 210 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

4 Customer Reviews

  • Cleaved caspases and p-H2AX expression were detected by western blot in HCT116 cells (E) and HT29 cells (F). The cells were co-cultured with F. nucleatum or treated with CQ, and different concentrations of Oxaliplatin and 5-FU.

    Cell, 2017, 170(3):548-563.e16. Oxaliplatin purchased from Selleck.

    Immunocytochemical staining of SW620 (metastatic) cells after treatment with 10 uM oxaliplatin (F) or 10 uM ginsenosides 20(S)-Rg 3 (G) and negative staining (H). Cells demonstrated differential expression of histone H4.

    J Proteomics 2014 10.1016/j.jprot.2014.10.009. Oxaliplatin purchased from Selleck.

  • PDT and oxaliplatin combination treatment. A) Bar graph showing response (total volume of residual viale nodules normalized to no treatment control) to PDT treatmen (2.5 J/cm2), oxaliplatin treatment (10 μM), and PDT followed by oxaliplatin at the same doses. The dramatic enhancement, beyond the additive effect of the two modalities independently suggests there may be a synergistic interaction. B) A representative region from a culture stained with calcein AM and ethidium bromide following treatment with the PDT + oxaliplatin combination shows relatively small pockets of viable disease and many dead relative to untreated cultures.

    Optical Methods for Tumor Treatment and Detection 2013 10.1117/12.2010730. Oxaliplatin purchased from Selleck.

     

    Growth inhibitory effects of Oxaliplatin in human pancreatic cancer cells. MiaPaCa-2 cells were plated in triplicates into 48-well plates at a density of 10,000 cells/ml. After 24 hours, complete culture medium was changed into fresh low-serum-containing medium (1% FBS) containing DMSO (control) or indicated doses of Oxaliplatin (Selleckchem). Cell viability 72 hours after treatment was determined by AlamarBlue assay (Invitrogen) according to manufacturer's instructions. Results are expressed as percentages of control, which was arbitrarily assigned 100% viability, and represented as the mean ± standard deviation (SD) of the tripicate wells. 

    2013 Dr. Edita Aksamitiene from Thomas Jefferson University. Oxaliplatin purchased from Selleck.

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Biological Activity

Description Oxaliplatin inhibits DNA synthesis by conforming DNA adducts in RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2, and HT-144 cells.
Targets
DNA synthesis [1]
(RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2, HT-144 cells)
In vitro

The main mechanism of action of Oxaliplatin is mediated through the formation of DNA–adducts. Oxaliplatin induces primary and secondary DNA lesions that lead to cell apoptosis. [1] Oxaliplatin is active against human melanoma cell lines C32 and G361 with IC50 of 0.98 mM and 0.14 mM, respectively. [2] Oxaliplatin effectively inhibits bladder carcinoma cell lines RT4 and TCCSUP, ovarian carcinoma cell line A2780, colon carcinoma cell line HT-29, glioblastoma cell lines U-373MG and U-87MG, and melanoma cell lines SK-MEL-2 and HT-144 with IC50 of 11 μM, 15 μM, 0.17 μM, 0.97 μM, 2.95 μM, 17.6 μM, 30.9 μM and 7.85 μM, respectively. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HKESC-2 M3rycGN6fG:2b4jpZ4l1gSCDc4PhfS=> NX:0ZZZHOOLCk{G2NOKh|ryP MYi0POKhcA>? NWLac3I6UUN3ME21MljDqMLzwrCwMlUh|ryP NUHme4pSOjZ2N{S2PVM>
CaES-17 MV;DfZRwfG:6aXPpeJkhSXO|YYm= MXiw5qCUOTZywrFOwG0> M1m2NFQ5yqCq NGrKNVhKSzVyPUWuOeKhyrIEoECuNkDPxE1? MmXNNlY1PzR4OUO=
SW480 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXK0PEBpyqB? MYrJR|UxRTFwOEeg{txO M{LhU|I3OjZ7N{W5
HCT116 M2XLS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2naWFQ5KGkEoB?= NEXoVYRKSzVyPUGxMlg3KM7:TR?= M2TJcFI3OjZ7N{W5
LoVo NHLXUHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWLCXGQxPDhiaNMg NVG0VXFVUUN3ME25OE45OyEQvF2= MnjBNlYzPjl5NUm=
SK-BR-3 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3[5cWlEPTB;M{GuNEDDuSByLkGg{txO MnLQNlYzOTF3OUG=
MCF-7 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;qSFRKSzVyPUG1MlQhyrFiMD6zJO69VQ>? MVeyOlIyOTV7MR?=
MDA-MB-231 Mk[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\acGlEPTB;MkOuNUDDuSByLkGg{txO MVGyOlIyOTV7MR?=
HCT116 p53+/+ NETI[nlHfW6ldHnvckBCe3OjeR?= NFvMVXoyNzVizszN NFj4b2QzPC92ODDo M4PMfolv\HWlZYOgeJJidnOlcnnweIlwdmGuIILldJJme3Orb36gc4YhTFWWLV6= MUOyOlIxQDV{Mx?=
LoVo  NVW0eJhHTnWwY4Tpc44hSXO|YYm= MnXENU82KM7:TR?= MXyyOE81QCCq Mni2bY5lfWOnczD0doFve2O{aYD0bY9v[WxicnXwdoV{e2mxbjDv[kBFXVRvTh?= MmrWNlYzODh3MkO=
SNU-398 MoX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlu4TWM2OD14LkZCpOKyyqBzLkGg{txO NX3xfYRPOjZzNkC0Nlk>
Hep-G2 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEC1flNKSzVyPUGzMlHDqMLzwrCxMlYh|ryP MWmyOlE3ODR{OR?=
SNU-475 M33xcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlP1TWM2OO,:nkOwJO69VQ>? M4TnSlI3OTZyNEK5
SNU-387 NUjPUJc6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1rkRWlEPTB;MkZCpOKyyqB{Lkeg{txO M161UVI3OTZyNEK5
HT29 NWT0dYF6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPoTWM2OD1yLki4xsDDucLiMD6yJO69VQ>? MVKyOlE1QDV7Nh?=
HCT116 Mn30S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzv[mZlUUN3ME2wMlQyyqEEsdMgNE4xOiEQvF2= NVvOdVdOOjZzNEi1PVY>
PA-1 M4fVSGNmdGxiVnnhZoltcXS7IFHzd4F6 MmPuNE0zOCEQvF2= NVTV[HJiOjRxNEigbC=> M4PX[YlvcGmkaYTzJINmdGxidnnhZoltcXS7IHnuJIJwfGhidHnt[UBidmRiZH;z[UBl\XCnbnTlcpQhdWGwbnXy NVzCbGo5OjZzM{i2O|E>
OVCAR-5 NEfRdGRE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MmXoNE03OCEQvF2= NGPkOGwzPC92OD:3NkBp Moi2bY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliaX6gZo91cCC2aX3lJIFv\CCmb4PlJIRmeGWwZHXueEBu[W6wZYK= MWeyOlE{QDZ5MR?=
SK-OV-3 M{HnNmNmdGxiVnnhZoltcXS7IFHzd4F6 NGHpXnExNTFyMDFOwG0> NGCzcGozPC92OD:3NkBp NV72[45wcW6qaXLpeJMh[2WubDD2bYFjcWyrdImgbY4h[m:2aDD0bY1mKGGwZDDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> MVqyOlE{QDZ5MR?=
PA-1 M1HuNmZ2dmO2aX;uJGF{e2G7 NHnYOnkyOCEQvF5CpC=> NVLh[Y5kOjSq NFnOZWF1emmpZ3Xy[ZMhfGinIIDyc4R2[3Srb36gc4YhfHmyZTDJJGlHVnNiYX7kJINp\W2xa3nu[ZM> MVmyOlE{QDZ5MR?=
OVCAR-5 MV;GeY5kfGmxbjDBd5NigQ>? NFf4d3M{OCEQvF2= M2HoWlQ5cA>? M4\SbZRzcWepZYLld{B1cGVicILv[JVkfGmxbjDv[kB1gXCnIFmgTWZPeyCjbnSgZ4hmdW:taX7ldy=> NInmOI0zPjF|OE[3NS=>
SK-OV-3 M2qzVWZ2dmO2aX;uJGF{e2G7 NFLHRnU2OCEQvF2= MnzSPVYhcA>? MUj0dolo\2W{ZYOgeIhmKHC{b3T1Z5Rqd25ib3[geJlx\SCLIFnGUpMh[W6mIHPo[Y1wc2mwZYO= M3zqUFI3OTN6Nkex
PA-1 MmPmSpVv[3Srb36gRZN{[Xl? MWKxNEDPxE4EoB?= MnL5OFhp M3TROJVxNXKnZ4XsZZRmeyC2aHWgd5Rz\XO|IHzp[4Fv\HNiZn;yJG5MKGOnbHytZYN1cX[jdHnu[{Bz\WOncITvdpMh[W6mIGTSRWlNKHKnY3XweI9zew>? MUOyOlE{QDZ5MR?=
OVCAR-5 M33wb2Z2dmO2aX;uJGF{e2G7 M4npTlMxKM7:TR?= NX7wcpZjPDiq MlzNeZAuemWpdXzheIV{KHSqZTDzeJJme3NibHnnZY5leyCob4KgUmsh[2WubD3hZ5RqfmG2aX7nJJJm[2WydH;yd{BidmRiVGLBTWwhemWlZYD0c5J{ NXT6S4dqOjZzM{i2O|E>
SK-OV-3 MWrGeY5kfGmxbjDBd5NigQ>? M1v0[VUxKM7:TR?= MnLMPVYhcA>? NU\ZSoF4fXBvcnXneYxifGW|IITo[UB{fHKnc4OgcIlo[W6mczDmc5IhVktiY3XscE1i[3SrdnH0bY5oKHKnY3XweI9zeyCjbnSgWHJCUUxicnXj[ZB1d3K| Mli1NlYyOzh4N{G=
PA-1 NF;5dHBHfW6ldHnvckBCe3OjeR?= NUmxSZl1OTBizszNxsA> NH3TPW0zPGh? MUTwdo9ud3SnczDz[Y5{cXSrdnn0fUBw\iCxdnHybYFvKGOjcnPpco9u[SC2bzDOT{Bk\WyuLX3l[IlifGWmIHP5eI9tgXOrcx?= M{PqRVI3OTN6Nkex
OVCAR-5 M2X1WWZ2dmO2aX;uJGF{e2G7 Mne3NlAh|ryPwrC= Mk\LNlRp NFrZbWlxem:vb4Tld{B{\W6|aYTpeol1gSCxZjDveoFzcWGwIHPhdoNqdm:vYTD0c{BPUyClZXzsMY1m\GmjdHXkJIN6fG:ueYPpdy=> M3\MblI3OTN6Nkex
SK-OV-3 M1jnbGZ2dmO2aX;uJGF{e2G7 MnrCOVAh|ryPwrC= MoPFOFghcMLi M13h[JBzd22xdHXzJJNmdnOrdHn2bZR6KG:oIH;2ZZJq[W5iY3HyZ4lvd22jIITvJG5MKGOnbHytcYVlcWG2ZXSgZ5l1d2y7c3nz M1T4cVI3OTN6Nkex
CT26  MW\GeY5kfGmxbjDBd5NigQ>? NH;hRnY1KG2P NIn2cXY1QCCqwrC= MmXKbY5lfWOnczDheZRweGijZ4m= M1HZc|I3OTN5MEGy
CT26  NXXrUWluTnWwY4Tpc44hSXO|YYm= MlzIOEBuVQ>? NVy4UnF[PDhiaNMg MknTbY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIHzleoVteyCxZjDheZRweGijZ4mtdoVt[XSnZDDwdo91\Wmwczygd5VkcCCjczDMR|MuUUluIFLlZ4xqdjFiYX7kJGFVTzV? NFrBdZAzPjF|N{CxNi=>
CT26  MkTBR4VtdCCYaXHibYxqfHliQYPzZZk> NH7QPWg1KG2P MoHhOFghcMLi MljE[IVkemWjc3XzJINmdGxidnnhZoltcXS7IITvJFU{NjJn NXHx[2xqOjZzM{ewNVI>
BE NXnFeHJrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTNwM{Og{txO MYiyOlAzOzB6NR?=
Colo205 M1HtdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmfqTWM2OD1|LkOzJO69VQ>? M3OwW|I3ODJ|MEi1
DLD1 Mli1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHqNo9KSzVyPUKuNFEh|ryP M4jS[FI3ODJ|MEi1
HT29 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\XcGlEPTB;Mj62PUDPxE1? M2XaOVI3ODJ|MEi1
HCT15 MkLvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvIVItKSzVyPUGuOFMh|ryP NV;VS4NsOjZyMkOwPFU>
HCT116 MmK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;JTWM2OD1zLkC0JO69VQ>? NXvYfWxROjZyMkOwPFU>
HCT116p53- Mmi4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jqNGlEPTB;MT6wPEDPxE1? MkTHNlYxOjNyOEW=
KM12 NHfzS|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13iT2lEPTB;ND6zO{DPxE1? NH7lTXMzPjB{M{C4OS=>
LoVo M3K4OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo[2TWM2OD1zLkKg{txO MUOyOlAzOzB6NR?=
RKO NF\xeHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLqTWM2OD1zLkKzJO69VQ>? Ml3zNlYxOjNyOEW=
SW480 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGS2b|NKSzVyPUKuPFYh|ryP MkKwNlYxOjNyOEW=
SW620 NEjVc|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7wTWM2OD1|Lk[4JO69VQ>? M2nqZVI3ODJ|MEi1
MC38 NYfVRmFUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\oSlVlUUN3ME2yN{DPxE1iwsGgNi=> NXvU[4lrOjZyMESwPFQ>
HT29 NH;QU2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHr1OZBKSzVyPU[zJO69VSEEsTCxPC=> MWmyOlAxPDB6NB?=
DLD-1 NYjBOlFGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTN{LkKg{txO NV3MTmlpOjZyMEOwPFU>
HT-29 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XWTmlEPTB;M{WuOkDPxE1? M3TvdFI3ODB|MEi1
SiHa M2PxbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTBwODFCtUAxNjFizszN MnG3NlU5ODFyMEe=
S3 NInYZ3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHftfmZKSzVyPUWzMlUhyrFiMT61JO69VQ>? MkTGNlU5ODFyMEe=
AGS NXSwbVk2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVWxOmtLUUN3ME2xNE43KM7:TR?= NXnlUZVJOjV5OEmwOVc>
MKN-45 NXvWSJRIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTF2LkCg{txO NVXsbXl5OjV5OEmwOVc>
TMK-1 Mo\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPtTWM2OD1{Mj62JO69VQ>? M3L4RVI2Pzh7MEW3
SCM-1 NVG5VGRyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTF5LkWg{txO M{DPW|I2Pzh7MEW3
HCT-15 M2LHN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRThwNkSg{txO MWWyOVc3OTR5OR?=
DiFi MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLRTWM2OD1zMD65OUDPxE1? M{\QdFI2PzZzNEe5
DLD-1 M{nIT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\3d2lEPTB;OD62OUDPxE1? M3HKWFI2PzZzNEe5
COLO-320DM M4nvfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nsXGlEPTB;NT6zPEDPxE1? M2LNUFI2PzZzNEe5
SNU-175 NHq5cVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2P5c2lEPTB;MT61NUDPxE1? MUSyOVc3OTR5OR?=
HT-29 NF36cZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkTnTWM2OD13LkKyJO69VQ>? MoCwNlU4PjF2N{m=
SW620 Ml:5SpVv[3Srb36gRZN{[Xl? M3O3UFEx6oDLwsXnM41t NEX2WXMzPOLCiXi= NHjRVmRqdmO{ZXHz[ZMhVEN|LVnJJIFk[3WvdXzheIlwdiCjbnSg[IVkemWjc3XzJHA3OiCneIDy[ZN{cW:w NXPlb4JTOjV5NEm0NlA>
SW480 MlXtSpVv[3Srb36gRZN{[Xl? NEnsOFQyOOLCidM1[{9udA>? MUmyOQKBkWh? MmTIbY5kemWjc3XzJGxEOy2LSTDhZ4N2dXWuYYTpc44h[W6mIHTlZ5Jm[XOnczDQOlIh\XiycnXzd4lwdg>? MYqyOVc1QTR{MB?=
SW620 M1ruXGZ2dmO2aX;uJGF{e2G7 MkDPNVDjiIoEtXevcYw> NWO1R4ZDOjUkgJno NHT2TIRmdmijbnPld{Bk\WyudXzhdkBifXSxcHjh[4lkKG[udYi= M1W5d|I2PzR7NEKw
SW480 NUPEZ3l7TnWwY4Tpc44hSXO|YYm= M1LuW|Ex6oDLwsXnM41t MmS5NlTjiImq M1v2Z4VvcGGwY3XzJINmdGy3bHHyJIF2fG:yaHHnbYMh\my3eB?= M16wfFI2PzR7NEKw
A549 MnnLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkT0TWM2OD13LkigxtEhOC54IN88US=> M2XFPFI2PjJ3MkSz
A549/CDDP NVGzWHlqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTF6Lk[gxtEhOS5{IN88US=> Mn3xNlU3OjV{NEO=
Panc-1 NVHwU2pZS2WubDDWbYFjcWyrdImgRZN{[Xl? M1XmUVI2NzVyIN88US=> NHPZW4EzPC92ODDo NYHRbI1GcW6qaXLpeJMheHKxbHnm[ZJifGmxbjDv[kBRSyClZXzsd{BqdiCjIIP5coVz\2m|dHnjJI1idm6ncjDjc41jcW6nZDD3bZRpKFeD M3rSPVI2PDR2OUG0
MIAPaCa-2 MWfD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MYGyOU82OCEQvF2= M{nkbVI1NzR6IHi= NIH3V25qdmirYnn0d{Bxem:uaX\ldoF1cW:wIH;mJHBEKGOnbHzzJIlvKGFic4nu[ZJocXO2aXOgcYFvdmW{IHPvcYJqdmWmIIfpeIghX0F? NXPwdmF{OjV2NES5NVQ>
SW1990 M2LON2NmdGxiVnnhZoltcXS7IFHzd4F6 MlvqNlUwPTBizszN NGHh[VMzPC92ODDo M2XYbIlvcGmkaYTzJJBzd2yrZnXyZZRqd25ib3[gVGMh[2WubIOgbY4h[SC|eX7ldodqe3SrYzDtZY5v\XJiY3;tZolv\WRid3n0bEBYSQ>? M1;KTFI2PDR2OUG0
HPDE Mn7xR4VtdCCYaXHibYxqfHliQYPzZZk> NUTUfFlvOjVxNUCg{txO MYWyOE81QCCq NWfKeVg1cW6qaXLpeJMheHKxbHnm[ZJifGmxbjDv[kBRSyClZXzsd{BqdiCjIIP5coVz\2m|dHnjJI1idm6ncjDjc41jcW6nZDD3bZRpKFeD NIexe5AzPTR2NEmxOC=>
Panc-1 M{THdWFxd3C2b4Ppd{BCe3OjeR?= M{nFflI26oDLwsXN MorzNlQhcA>? NUi5NGJUcW6mdXPld{BieG:ydH;zbZMhcW5iYTDzfY5memerc4TpZ{Bu[W6wZYKgZ49u[mmwZXSge4l1cCCZQR?= NHjFOW8zPTR2NEmxOC=>
MIAPaCa-2 M1HDN2Fxd3C2b4Ppd{BCe3OjeR?= MlzENlXjiIoEtV2= MYCyOEBp MkfLbY5lfWOnczDhdI9xfG:|aYOgbY4h[SC|eX7ldodqe3SrYzDtZY5v\XJiY3;tZolv\WRid3n0bEBYSQ>? M3zOe|I2PDR2OUG0
Panc-1 NH3scHNHfW6ldHnvckBCe3OjeR?= MnXkNlXjiIoEtV2= NESyemczPC92ODDo MnrFbY5lfWOnczDjcIVifmGpZTDv[kBRSVKSLDDjZZNx[XOnLUmsJINie3Cjc3WtPEBidmRiY3HzdIF{\S1|wrC= NFXXV4YzPTR2NEmxOC=>
MIAPaCa-2 NGjDb4xHfW6ldHnvckBCe3OjeR?= MUSyOgKBkcL3TR?= MmqwNlQwPDhiaB?= MWTpcoR2[2W|IHPs[YF3[WenIH;mJHBCWlBuIHPhd5Bie2VvOTygZ4F{eGG|ZT24JIFv\CClYYPwZZNmNTQEoB?= MmHrNlU1PDR7MUS=
SW480 NUTKNmtyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPVW5k4OiCqwrC= MU\JR|UxRTFyLkhCtVIvOjZiwsXnM41N MUOyOVM3ODZ|MR?=
HCT116  MkHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHjb2lCPzJiaNMg MVTJR|UxRTZwMkRCtVAvPzViwsXnM41N M2iye|I2OzZyNkOx
COC1 MnjJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXmPWRpUUN3ME20Ok4zOMLiwsJCpFMvOTRizszN MVWyOVMxPzR2OB?=
SGC7901 M{DnWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTJzLkezxsDDucLiMz6wPEDPxE1? M13rZVI2OzB5NES4
A549 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX61bVIxUUN3ME21NU4xQMLiwsJCpFExNjl4IN88US=> NWHJfGlNOjV|MEe0OFg>
HepG2 MkXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGXxOIJKSzVyPUG0MlI1yqEEsdMgNU45OiEQvF2= M{f4XFI2OzB5NES4
MCF-7 M4nNc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTF2LkK0xsDDucLiMT64NkDPxE1? M{TsS|I2OzB5NES4
HCT-116 M3;pb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fpUmlEPTB;Nj6yOOKhyrIEoEKuPVch|ryP M{\yUFI2OzB5NES4
HT-29 NG\vXoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRjVyIN88US=> MoWzNlU{ODd2NEi=
HEK293 M1K3dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLVNlVKSzVyPUiuPFLDqMLzwrC1MlU6KM7:TR?= NIXNNZczPTNyN{S0PC=>
HUVEC MljDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTFR3BKSzVyPUGxMlMxyqEEsdMgNU4xOiEQvF2= M3T0PVI2OzB5NES4
SW480 M2KzVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XrSFHDqM7:TR?= MVKwMVczKGh? NGPiXW9qdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJJRqdWViZHXw[Y5l\W62IH3hco5meg>? MWeyOFk6PzR3MR?=
HT-29 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnOdYFsOcLizszN M4i2SVAuPzJiaB?= MXvpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIITpcYUh\GWyZX7k[Y51KG2jbn7ldi=> Mn61NlQ6QTd2NUG=
HCT116 MknVSpVv[3Srb36gRZN{[Xl? M3vFdlIwPSEEtV2= M16wblI1NzR6IHi= NGD1b5p{fXCycnXzd4V{KHO3co\peolvKG2UTlGg[ZhxemW|c3nvci=> NUK1eVhbOjR5NkG0NVE>
SW480  NHjwfVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWK0PEBpyqB? MmnpTWM2OD1{MD64JJVoN22O M3;yOFI1PzJyNke1
SW620 M3[2cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTQb5MyOC15MDDt[{9N Mk\BNlQwPDhxN{KgbC=> MlH1bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nIHHu[EBld3OnIHTldIVv\GWwdDDtZY5v\XJ? MXmyOFY1PjNyNR?=
Caco2  NXHhUY5TTnWwY4Tpc44hSXO|YYm= MUWzNOKh|ryP MUeyOEBp M4DoU2ROW09? MUjpcoR2[2W|IITo[UBmgHC{ZYPzbY9vKG:oIFjPMVEtKEGNUkHDMEBidmRiTmHPNS=> NV;vWno4OjR3NU[0NVU>
Caco2  M3X3dGZ2dmO2aX;uJGF{e2G7 M1\aOVMwOTBxM{Cg{txO MXyxOkBp MXjEUXNQ M3rGR4lv[3KnYYPld{B1cGVibWLORUBt\X[nbIOgc4bDqEGNUkHDNUwhVlGRMTygTG8uOSxiTWLQNkzDqGGwZF3SVFPDqGSxc3Wt[IVx\W6mZX70cJk> NHPLNGkzPDV3NkSxOS=>
Caco2 Ml3tSpVv[3Srb36gRZN{[Xl? NXrnXoQ3OzBxMUCwxsDPxE1? MVqxOuKhcA>? NYXNUVdyTE2VTx?= MoLOZYN1cX[jdHXzJG5z\jJ? M2Dqc|I1PTV4NEG1

... Click to View More Cell Line Experimental Data

In vivo A weekly i.p. injection of Oxaliplatin at 10 mg/kg to nude mice bearing hepatocellular HCCLM3 tumors significantly reduces tumor volume and apoptotic index. [6] Oxaliplatin (5mg/kg, i.v. on days 1, 5 and 9) is active on T-leukemia-lymphoma L40 AKR with T/C of 1.77. Oxaliplatin is also efficient on intracerebrally grafted L1210 leukemia, MA 16-C xenografts, B16 melanoma xenografts, Lewis lung xenografts and C26 colon carcinoma xenografts. [7] Oxaliplatin induces impairment of retrograde neuronal transport in mice. [8]

Protocol

Cell Research:[4]
+ Expand
  • Cell lines: RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2 and HT-144 cell lines
  • Concentrations: ~100 μM
  • Incubation Time: 48 hours
  • Method: The cytotoxicity studies are carried out with the sulforhodamine-B microculture colorimetrie assay. Typically, cells are plated into 96-well plates on day 0 and exposed to Oxaliplatin on day 1; the sulforhodamine-B assay is carried out 48 h after Oxaliplatin exposure. The plates are incubated at 37 °C in 5% CO2 and 100% relative humidity at all times except when adding Oxaliplatin and during the final assay period. The initial number of cells plated for the assay ranged from 2-20 × 103 cells/50 /nL/well. The numbers of cells for plating and the drug exposure time are based on pilot studies using the criteria that (a) the cells in control wells are still in the log phase of growth on the day of the assay; (b) the maximum absorbance for the untreated controls on the day of the assay is in the range of 1.0 to 1.5; and (c) cells go through >2 doublings during the drug exposure. Eight wells are used per concentration. The plates are read at 570 and/or 540 nm using a Biotek Instruments model EL309 microplate reader interfaced with an IBM PC-compatible computer. The data are transferred and transformed into a LOTUS 1-2-3 format by the computer program DATALOG, and survival fractions are calculated by comparing the drug treated with control
    (Only for Reference)
Animal Research:[6]
+ Expand
  • Animal Models: Human hepatocellular carcinoma xenografts HCCLM3
  • Formulation: Water solution
  • Dosages: 10 mg/kg
  • Administration: A weekly i.p. injection
    (Only for Reference)

Solubility (25°C)

In vitro Water 3 mg/mL warmed (7.55 mM)
Ethanol 0.01 mg/mL (0.02 mM)
DMF Insoluble
In vivo Add solvents individually and in order:
5% glucose (with warming)
3mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 397.29
Formula

C8H14N2O4Pt

CAS No. 61825-94-3
Storage powder
Synonyms L-OHP

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01928290 Recruiting Stomach Neoplasms|Esophageal Neoplasms Washington University School of Medicine November 8, 2013 Phase 2
NCT03050814 Not yet recruiting Colorectal Cancer National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) February 3, 2017 Phase 2
NCT02997228 Not yet recruiting Colorectal Adenocarcinoma|High-Frequency Microsatellite Instability|Stage IV Colorectal Cancer|Stage IVA Colorectal Cancer|Stage IVB Colorectal Cancer National Cancer Institute (NCI) November 2017 Phase 3
NCT02912559 Not yet recruiting Colon Adenocarcinoma|DNA Repair Disorder|Lynch Syndrome|Microsatellite Instability|Stage IIIA Colon Cancer|Stage IIIB Colon Cancer|Stage IIIC Colon Cancer National Cancer Institute (NCI) September 2017 Phase 3
NCT03043729 Not yet recruiting Rectal Cancer|Rectosigmoid Cancer AIO-Studien-gGmbH|Institut für Klinisch-Onkologische Forschung (IKF) Frankfurt|Sanofi February 2017 Phase 2
NCT03000374 Not yet recruiting Rectal Cancer Grupo Espanol Multidisciplinario del Cancer Digestivo|Pivotal S.L.|Amgen February 2017 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Is it ok to dissolve Oxaliplatin in DMSO?

  • Answer:

    Even though cis-platin is soluble in DMSO, the use of DMSO to dissolve cis– or trans-diamminedichloroplatinum (DDP) in biological studies is strongly discouraged. The DMSO inserts itself into the ligand and inactivates platin-containing compounds. DMF is a much better choice than DMSO.

Related Antibodies

DNA/RNA Synthesis Signaling Pathway Map

Related DNA/RNA Synthesis Products

Tags: buy Oxaliplatin | Oxaliplatin supplier | purchase Oxaliplatin | Oxaliplatin cost | Oxaliplatin manufacturer | order Oxaliplatin | Oxaliplatin distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID